Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | January 02, 2026 | January 07, 2026 |
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | May 20, 2026 | May 21, 2026 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 15,532 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 3,032 · Balance 15,532 F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2: Each RSU represents a contingent right to receive one ordinary share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2036-01-02 | Direct | 6,065 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 6,065 · Balance 6,065 F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20 | Direct | 41,800 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800 F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. F2: Options to vest 100% on May 20, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 34,200 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200 F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027. F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
F2: Options to vest 100% on May 20, 2027.
F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kronos Bio, Inc.
Report date June 20, 2025 · Filed June 20, 2025
Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.28 · Expires 2033-04-19 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-20 · Disposition to issuer · Disposed 68,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-20 · Disposition to issuer · Disposed 5,868 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2034-06-24 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]
F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Seagen Inc.
Report date December 14, 2023 · Filed December 15, 2023
Section 16 reporting ended · disclosed 2023-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Disposition to issuer · Disposed 38,338 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.11 · Expires 2028-06-15 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-14 · Disposition to issuer · Disposed 6,140 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.64 · Expires 2029-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-14 · Disposition to issuer · Disposed 1,333 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.64 · Expires 2029-08-30 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-14 · Disposition to issuer · Disposed 18,083 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.82 · Expires 2030-08-17 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-14 · Disposition to issuer · Disposed 636 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.82 · Expires 2030-08-17 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-14 · Disposition to issuer · Disposed 32,073 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $155.87 · Expires 2031-08-16 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-12-14 · Disposition to issuer · Disposed 642 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $155.87 · Expires 2031-08-16 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-12-14 · Disposition to issuer · Disposed 41,250 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $137.96 · Expires 2032-11-09 | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-12-14 · Disposition to issuer · Disposed 154,000 · Balance 0 F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-12-14 · Disposition to issuer · Disposed 3,298 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-12-14 · Disposition to issuer · Disposed 8,586 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-12-14 · Disposition to issuer · Disposed 33,468 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-12-14 · Disposition to issuer · Disposed 2,260 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-12-14 · Disposition to issuer · Disposed 25,747 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-12-14 · Disposition to issuer · Disposed 4,756 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2023-12-14 · Disposition to issuer · Disposed 11,900 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2023-12-14 · Disposition to issuer · Disposed 1,717 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2023-12-14 · Disposition to issuer · Disposed 10,184 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2023-12-14 · Disposition to issuer · Disposed 16,547 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2023-12-14 · Disposition to issuer · Disposed 41,174 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2023-12-14 · Disposition to issuer · Disposed 4,291 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2023-12-14 · Disposition to issuer · Disposed 2,575 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2023-12-14 · Disposition to issuer · Disposed 4,980 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2023-12-14 · Disposition to issuer · Disposed 13,279 · Balance 0 F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2023-12-14 · Disposition to issuer · Disposed 1,827 · Balance 0 F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2023-12-14 · Disposition to issuer · Disposed 3,432 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2023-12-14 · Disposition to issuer · Disposed 8,582 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-12-14 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2023-12-14 · Disposition to issuer · Disposed 5,149 · Balance 0 F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance. F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
F2: Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.
F5: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
F6: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance.
F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU.
F8: Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2021 Filed May 17, 2021 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000042 · wf-form4_162128304958505.xml · derivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares will vest on May 13, 2022; 12,000 shares will vest on May 13, 2023; 12,000 shares will vest on May 13, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares will vest on May 13, 2022; 12,000 shares will vest on May 13, 2023; 12,000 shares will vest on May 13, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares will vest on May 13, 2022; 12,000 shares will vest on May 13, 2023; 12,000 shares will vest on May 13, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| May 13, 2021 Filed May 17, 2021 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Options · Derivative | 54,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001055726-21-000042 · wf-form4_162128304958505.xml · derivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2031-05-13 F1 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The vesting schedule for the 54,000 options is as follows: 13,500 shares vested on May 13, 2021; 13,500 shares will vest on May 13, 2022; 13,500 shares will vest on May 13, 2023; 13,500 shares will vest on May 13, 2024. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 20:08 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerCommon Stock | 728 | $163.97 | $119,370.16 |
DisclosureSEC source: 0001203311-21-000006 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,544 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 51 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 29, 2021. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 21:38 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 359 | $177.07 | $63,566.34 |
DisclosureSEC source: 0001203311-20-000124 · edgardoc.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,221 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 21:38 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 7,302 | $177.00 | $1,292,454.00 |
DisclosureSEC source: 0001203311-20-000124 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,580 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 19:25 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 169 | $155.69 | $26,312.32 |
DisclosureSEC source: 0001203311-20-000104 · edgardoc.xml · nonDerivative · entry 3 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,882 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 19:25 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 741 | $155.69 | $115,369.40 |
DisclosureSEC source: 0001203311-20-000104 · edgardoc.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,051 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 19:25 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 3,701 | $155.69 | $576,224.23 |
DisclosureSEC source: 0001203311-20-000104 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,792 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:40 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 32,073 | $0.00 Strike: $161.82 | $0.00 |
DisclosureSEC source: 0000899243-20-022644 · doc4.xml · derivative · entry 4 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,073 Underlying: Common Stock · 32,073 shares Expires 2030-08-17 F5 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:40 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 636 | $0.00 Strike: $161.82 | $0.00 |
DisclosureSEC source: 0000899243-20-022644 · doc4.xml · derivative · entry 3 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636 Underlying: Common Stock · 636 shares Expires 2030-08-17 F5 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:40 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 450 | $157.79 | $71,006.04 |
DisclosureSEC source: 0000899243-20-022644 · doc4.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,493 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 143 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on 7/31/2020. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 21:40 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022644 · doc4.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,943 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of August 15, 2020 until all shares are fully vested at the end of four years. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 143 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on 7/31/2020. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 17:54 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 962 | $160.10 | $154,016.20 |
DisclosureSEC source: 0001203311-20-000058 · edgardoc.xml · nonDerivative · entry 3 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,608 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $159.91 to $160.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 17:54 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 300 | $158.47 | $47,541.00 |
DisclosureSEC source: 0001203311-20-000058 · edgardoc.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,570 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $158.45 to $158.51. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 17:54 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 900 | $157.74 | $141,966.00 |
DisclosureSEC source: 0001203311-20-000058 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,870 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $157.40 to $157.97. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 19:24 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 838 | $157.15 | $131,691.70 |
DisclosureSEC source: 0001203311-20-000056 · edgardoc.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,770 F3 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 359 ESPP shares previously reported. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 19:24 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 4,984 | $157.15 | $783,235.60 |
DisclosureSEC source: 0001203311-20-000056 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,608 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 359 ESPP shares previously reported. Read SEC document |
| May 07, 2020 Filed May 8, 2020 19:42 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,912 | $0.00 Strike: $65.11 | $0.00 |
DisclosureSEC source: 0001203311-20-000030 · edgardoc.xml · derivative · entry 3 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,948 Underlying: Common Stock · 11,912 shares Expires 2028-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested at a rate of 25% on 5/21/19 and then monthly thereafter. All the shares shall be fully vested on 5/21/22. Read SEC document |
| May 07, 2020 Filed May 8, 2020 19:42 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 11,912 | $164.50 | $1,959,526.38 |
DisclosureSEC source: 0001203311-20-000030 · edgardoc.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,233 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $164.50 to $164.52. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| May 07, 2020 Filed May 8, 2020 19:42 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 11,912 | $65.11 | $775,590.32 |
DisclosureSEC source: 0001203311-20-000030 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| April 21, 2020 Filed Apr 21, 2020 21:58 UTC | Seagen Inc. SGEN · Entity 13956 | Disposition to issuerCommon Stock | 1,159 | $139.92 | $162,163.80 |
DisclosureSEC source: 0000899243-20-011117 · doc4.xml · nonDerivative · entry 4 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,233 F5 · shares: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F6 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 21:58 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 6,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011117 · doc4.xml · nonDerivative · entry 3 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,392 F2 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F4 · shares: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 12/31/2021, subject to continuous service with the Company until the vesting date. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 21:58 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,439 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011117 · doc4.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,487 F2 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F3 · shares: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 4/19/2022, subject to continuous service with the Company until the vesting date. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 21:58 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 2,389 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011117 · doc4.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,048 F1 · shares: The performance criteria for these restricted stock units were met. These restricted stock units became fully vested on 4/19/2020. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 17:33 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 350 | $116.33 | $40,715.50 |
DisclosureSEC source: 0000899243-20-005326 · doc4.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:08 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 727 | $108.51 | $78,886.77 |
DisclosureSEC source: 0001203311-20-000006 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,009 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 125 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 31, 2020. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 17:22 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029970 · doc4.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,611 F1 · security: These shares represent restricted stock units that will be settled in common stock upon vesting. F4 · date: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 12/18/2021, subject to continuous service with the Company until the vesting date. F3 · balance_after: Amount of securities beneficially owned following the reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 17:22 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 6,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029970 · doc4.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,051 F1 · security: These shares represent restricted stock units that will be settled in common stock upon vesting. F2 · date: The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 12/31/2021, subject to continuous service with the Company until the vesting date. F3 · balance_after: Amount of securities beneficially owned following the reported transactions includes restricted stock units subject to vesting. Read SEC document |
| December 16, 2019 Filed Dec 17, 2019 18:48 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 2,000 | $114.07 | $228,140.00 |
DisclosureSEC source: 0001203311-19-000069 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,146 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 17:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $65.11 | $0.00 |
DisclosureSEC source: 0000899243-19-028262 · doc4.xml · derivative · entry 3 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,860 Underlying: Common Stock · 5,000 shares Expires 2028-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested at a rate of 25% on 5/21/19 and then monthly thereafter. All the shares shall be fully vested on 05/21/22. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 17:32 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,000 | $121.48 | $607,388.00 |
DisclosureSEC source: 0000899243-19-028262 · doc4.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,146 F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $121.45 to $121.56. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 17:32 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 5,000 | $65.11 | $325,550.00 |
DisclosureSEC source: 0000899243-19-028262 · doc4.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 18:45 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $65.11 | $0.00 |
DisclosureSEC source: 0001203311-19-000061 · edgardoc.xml · derivative · entry 3 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,860 Underlying: Common Stock · 5,000 shares Expires 2028-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested at a rate of 25% on 5/21/19 and then monthly thereafter. All the shares shall be fully vested on 5/21/22. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 18:45 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,000 | $116.00 | $580,000.00 |
DisclosureSEC source: 0001203311-19-000061 · edgardoc.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,146 F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 18:45 UTC | Seagen Inc. SGEN · Entity 13956 | Exercise / conversionCommon Stock | 5,000 | $65.11 | $325,550.00 |
DisclosureSEC source: 0001203311-19-000061 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 18:12 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 490 | $74.24 | $36,377.60 |
DisclosureSEC source: 0001203311-19-000047 · edgardoc.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,146 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $74.23 to $74.28. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 18:12 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 2,510 | $73.72 | $185,037.20 |
DisclosureSEC source: 0001203311-19-000047 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,636 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $73.22 to $74.21. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:43 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 171 | $70.80 | $12,106.85 |
DisclosureSEC source: 0000899243-19-022787 · doc4.xml · nonDerivative · entry 3 DANSEY ROGER D · CIK 0001741836 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,146 F4 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 21:43 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 751 | $70.80 | $53,170.05 |
DisclosureSEC source: 0000899243-19-022787 · doc4.xml · nonDerivative · entry 2 DANSEY ROGER D · CIK 0001741836 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,317 F4 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:43 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 68,680 | $0.00 Strike: $72.64 | $0.00 |
DisclosureSEC source: 0000899243-19-022787 · doc4.xml · derivative · entry 5 DANSEY ROGER D · CIK 0001741836 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,680 Underlying: Common Stock · 68,680 shares Expires 2029-08-30 F5 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:43 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 1,333 | $0.00 Strike: $72.64 | $0.00 |
DisclosureSEC source: 0000899243-19-022787 · doc4.xml · derivative · entry 4 DANSEY ROGER D · CIK 0001741836 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2029-08-30 F5 · derivative.exercise_date: Options shall vest at a rate of 25% one year from grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 21:43 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 29,475 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-022787 · doc4.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,068 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 18:43 UTC | Seagen Inc. SGEN · Entity 13956 | SaleCommon Stock | 5,416 | $68.60 | $371,537.60 |
DisclosureSEC source: 0001203311-19-000022 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,593 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 16:39 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 5,768 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-004265 · doc4.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,009 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the vesting commencement date of February 1, 2019 until all shares are fully vested four years from the vesting commencement date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 359 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 31, 2019. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 19:29 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,010 | $0.00 Strike: $77.45 | $0.00 |
DisclosureSEC source: 0001203311-18-000085 · edgardoc.xml · derivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,010 Underlying: Common Stock · 14,010 shares Expires 2028-09-07 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date. Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 19:29 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 5,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-18-000085 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,241 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:49 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,189 | $0.00 Strike: $76.86 | $0.00 |
DisclosureSEC source: 0001203311-18-000075 · edgardoc.xml · derivative · entry 2 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,189 Underlying: Common Stock · 3,189 shares Expires 2028-08-30 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from the grant date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 20:49 UTC | Seagen Inc. SGEN · Entity 13956 | GrantCommon Stock | 1,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001203311-18-000075 · edgardoc.xml · nonDerivative · entry 1 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,343 F1 · security: These shares represent restricted stock units and will be settled in common stock upon vesting. F2 · date: Shares shall vest at a rate of 25% on each anniversary of the grant date until all shares are fully vested four years from the grant date. F3 · balance_after: Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 19:57 UTC | Seagen Inc. SGEN · Entity 13956 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 43,860 | $0.00 Strike: $65.11 | $0.00 |
DisclosureSEC source: 0001203311-18-000053 · edgardoc.xml · derivative · entry 4 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,860 Underlying: Common Stock · 43,860 shares Expires 2028-06-15 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 19:57 UTC | Seagen Inc. SGEN · Entity 13956 | GrantIncentive Stock Option (right to buy) · Derivative | 6,140 | $0.00 Strike: $65.11 | $0.00 |
DisclosureSEC source: 0001203311-18-000053 · edgardoc.xml · derivative · entry 3 DANSEY ROGER D · CIK 0001741836 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,140 Underlying: Common Stock · 6,140 shares Expires 2028-06-15 F4 · derivative.exercise_date: Shares shall vest at a rate of 25% one year from the grant date and monthly thereafter until all shares are fully vested four years from grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.